Screener
aTyr Pharma ATYR Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | $264 | $325 | $547 | $629 |
| General and administrative | 881 | 980 | 1,905 | 1,854 |
| Total stock-based compensation expense | $1,145 | $1,305 | $2,452 | $2,483 |
Item 1. Financial Statements
FAQ
- What is aTyr Pharma's stock-based comp?
- aTyr Pharma (ATYR) reported stock-based comp of $1.15M in Q2 2026.
- How has aTyr Pharma's stock-based comp changed year-over-year?
- aTyr Pharma's stock-based comp decreased by 12.3% year-over-year, from $1.31M to $1.15M.
- What is the long-term trend for aTyr Pharma's stock-based comp?
- Over 4 years (2021 to 2025), aTyr Pharma's stock-based comp has grown at a 32.6% compound annual growth rate (CAGR), from $1.61M to $5M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about aTyr Pharma's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude